PTX17885-MD4-1MG is a high-quality isotype control antibody developed by ProteoGenix, specifically designed for applications requiring a non-targeting control in antibody-drug conjugate (ADC) research. This molecule is based on the well-characterized HyHEL-10 monoclonal antibody, formatted as a human IgG1 with LALA Fc mutations, which abolish Fcγ receptor binding and effector functions, thereby minimizing background immune responses in experimental systems.
This antibody has been site-specifically conjugated to Monomethyl Auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline (c-ValCitPAB) linker, a widely used cleavable linker system in ADC development. The average Drug-to-Antibody Ratio (DAR) is 4, ensuring a controlled and reproducible payload loading, suitable for preclinical evaluations.
PTX17885 serves as an ideal negative control in ADC functional studies, in vitro cytotoxicity assays, and in vivo efficacy testing. Because it does not recognize any known mammalian antigen, it enables accurate interpretation of payload-specific or linker-specific effects in biological models without the interference of antigen-mediated targeting.
This product is particularly valuable for:
- Benchmarking ADC efficacy and toxicity
- Validating linker-drug combinations
- Assessing bystander effects and off-target cytotoxicity
- Comparative studies in ADC format optimization
PTX17885-MD4-1MG is a powerful tool for researchers working in ADC development, oncology drug discovery, and antibody engineering, enabling precise evaluation of conjugate-specific mechanisms independently of target antigen engagement.
There are no reviews yet.